Heron shares surge on positive pain drug data

Shares of Redwood City, CA-based Heron Therapeutics shot up 20% on its release of positive data from its Phase II clinical study of HTX-011 for treating post-operative pain in patients undergoing bunionectomy. The biotech says that all primary and secondary endpoints were met in the study of their drug, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam. Release